Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2000, p. 1418-1427, Vol. 44, No. 6
Wyeth-Ayerst Research, Pearl River, New York
Received 10 August 1999/Returned for modification 20 December
1999/Accepted 26 February 2000
Protein secretion is an essential process for bacterial growth, yet
there are few if any antimicrobial agents which inhibit secretion. An
in vivo, high-throughput screen to detect secretion inhibitors was
developed based on the translational autoregulation of one of the
central protein components, SecA. The assay makes use of a SecA-LacZ
fusion reporter construct in Escherichia coli which is
induced when secretion is perturbed. Several compounds, including two
natural product extracts, which had the ability to induce the reporter
fusion were identified and the MICs of these compounds for
Staphylococcus aureus strain MN8 were found to be Bacterial protein secretion is an
attractive target for antimicrobial chemotherapy because the secretion
machinery is highly conserved among bacterial species but is distinct
from its eukaryotic counterparts (10, 11, 14, 15, 27, 42,
43). In Escherichia coli, approximately 20% of the
total cellular protein is secreted across the cytoplasmic membrane
(30). The Sec-dependent pathway of secretion is a
multicomponent system consisting of at least seven proteins, five of
which are essential for cell viability (for a review, see reference
8). Homologs for several of the components have been
identified in both gram-negative and gram-positive bacteria, and
therefore it is considered likely that an inhibitor of this pathway
would have broad-spectrum activity.
Secreted proteins are produced as precursors containing signal
sequences. Those which are secreted via the Sec pathway are accompanied
to the membrane by SecB, a chaperone molecule (Fig. 1). SecA, an ATPase required for
translocation at the multisubunit translocase SecY-SecE-SecG, is found
associated with both the signal sequence of secretable proteins, and
also with the membrane at SecE-SecY-SecG. During translocation ATP is
hydrolyzed, the protein is inserted across the membrane, the signal
sequence is cleaved, and the protein is released.
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Identification and Analysis of Bacterial Protein Secretion
Inhibitors Utilizing a SecA-LacZ Reporter Fusion System

and
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
128
µg/ml. Enzyme-linked immunosorbent assay, Western blotting, and
immunoprecipitation techniques were used to analyze the affects of
these compounds on protein secretion. Six representative compounds presented here appear to be bona fide secretion inhibitors but were
found to have deleterious effects on membranes. It was concluded that,
while the method described here for identifying inhibitors of secretion
is valid, screens such as this, which are directed against the
membrane-bound portion of a pathway, may preferentially identify
compounds which affect membrane integrity.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (20K):
[in a new window]
FIG. 1.
Sec-dependent secretory pathway.
Expression of SecA appears to be a focal point of regulation for this
process (20, 24, 33) (Fig. 2).
SecA translation is autogenously regulated in response to changes in
secretion levels. secA is transcribed as the second gene in
an operon after geneX, an open reading frame of unknown
function. Under normal secretion conditions, SecA binds to its own
mRNA, blocking the ribosomal binding site, thus inhibiting initiation
of translation. If secretion is blocked, SecA releases its mRNA and
translation levels increase (25).
|
An E. coli cell-based screen was developed in which a SecA-LacZ reporter fusion was used to identify inducers of SecA expression with the presumption that among these inducers would be inhibitors of secretion. Active compounds were tested for antimicrobial activity. Effects on the secretion of the Staphylococcus aureus toxic shock syndrome toxin-1 (TSST-1) were analyzed to further define the effects of these compounds. Immunoprecipitation of pulse-labeled maltose binding protein (MBP) in E. coli was also used to explore the mechanism of action of several of the confirmed inhibitors. Finally, the effect of a subset of the compounds on potassium leakage and precursor utilization in E. coli, and on lysis of red blood cells (RBCs), was determined to identify potential pleiotropic effects on membrane integrity.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Bacterial strains.
Mc4100 is an E. coli strain
(F
araD139
(argF-lac)U169
rpsL 150 (Strr) relA1 flbB5301 deoC 1 ptsF2,5
rbsR) (4).
(secA-lacZ)f181(Hyb) (
PR9). The secA-lacZ fusion is
integrated at the secA locus.
PR9 contains
envA, geneX, secA, and the 5' portion
of mutT and provides wild-type secA function. An
imp 4214 allele and a rec allele were introduced
using P1 transduction (38). MM171-2 was provided by Don
Oliver (25, 32).
MN8 is an S. aureus clinical isolate shown to produce
TSST-1. MN8 was provided by Patrick Schlievert (36).
Assay for detection of protein secretion inhibitors.
MM171-2
imp rec was grown to an optical density at 650 nm
(OD650) of 0.025 (10-mm path length). Ten microliters of
test compound at 100 µg/ml was added to 90 µl of culture in 96-well
microtiter plates, and the plate was incubated at 37°C with shaking
for 60 min. The OD650 was read in a microtiter plate, and
50 µl of ZOB buffer was added. ZOB buffer was prepared by mixing a
4:1 ratio of Z buffer (0.074 M monobasic sodium phosphate, 0.126 M
dibasic sodium phosphate, 2 mM magnesium sulfate, 0.4 mM manganese
sulfate, hexadecyltrimethylammonium bromide [399 mg/liter], sodium
deoxycholate [199.5 mg/liter], and 0.174 M
-mercaptoethanol) with
o-nitrophenyl-
-D-galactopyranoside (ONPG) (8 mg/ml) in T-base (15.1 mM ammonium sulfate, 0.08 M dibasic potassium
phosphate, 0.044 M monobasic potassium phosphate, and trisodium citrate
[1 g/liter]). The OD405 initial was read. Plates were
incubated for 1 h at room temperature, and 50 µl of 1 M sodium carbonate-8 M urea was added to stop the reaction. The final
OD405 was read and the level of
-galactosidase produced
was calculated: (final OD405
initial
OD405/OD650. This number was divided by that
obtained with the negative control (i.e., no test compound) to
determine the level of SecA induction (a parameter referred to herein
as the fold induction value).
MIC determination for strain MN8. Susceptibility tests were performed by broth microdilution using standard methods (23). Briefly, serial twofold dilutions of compound were made in Mueller-Hinton broth and inoculated with a bacterial suspension to give a final inoculum of 105 CFU/ml. The MIC was defined as the lowest concentration preventing visible growth after 18 h of incubation at 35°C.
Western analysis of TSST-1 secretion. A stationary culture of S. aureus MN8 was diluted 1:100 in brain heart infusion medium and grown with shaking for 6 h at 37°C in the presence of compounds of interest at concentrations previously determined to approach growth-inhibitory levels. At 6 h culture density was determined at OD650 (10-mm path length) and samples were harvested and quantitatively normalized to the lowest OD. Cell pellets and medium were both retained. Cell pellets were resuspended in 100 µl of 10 mM Tris-HCl-1 mM EDTA (pH 8.0), and lysis was effected by 10 µg of lysostaphin at 37°C for 30 min and then at 65°C for 30 min. Gel loading dye containing sodium dodecyl sulfate (SDS) (37) was added, and samples were boiled prior to gel electrophoresis. Medium was also normalized based on the lowest cell culture OD650, combined with gel loading dye, and boiled. Samples were subjected to SDS-11% polyacrylamide gel electrophoresis (16) and transferred to nitrocellulose using an LKB Multiphor II system as recommended by the manufacturer (Amersham Pharmacia Biotech, Piscataway, N.J.). Western blot analysis was performed using a polyclonal antibody to TSST-1 (Toxin Technologies, Inc., Sarasota, Fla.) at a 1:5,000 dilution and detected by chemiluminescence using the enhanced chemiluminescence Western blotting chemiluminescence detection system (Amersham Pharmacia Biotech).
TSST-1 secretion detection by ELISA. S. aureus MN8 was diluted and incubated with test compounds, as described above, for 6 h at 37°C. Cell density was measured at OD600, and the culture was centrifuged to harvest the medium. The harvested medium was heated to 95°C for 5 min and then coated onto a protein-binding microtiter plate overnight in 0.2 M sodium carbonate, pH 9.4. The coated plate was assayed by enzyme-linked immunosorbent assay (ELISA) using the anti-TSST-1 antibody and spectrophotometric quantitation of horseradish peroxidase linked to a secondary antibody. The percent of TSST-1 present in the medium was compared with the percent inhibition of growth levels at the different concentrations of inhibitory compounds.
Whole-cell pulse-chase labeling and immunoprecipitation of MBP
from Mc4100.
MICs (as estimated by increase in the
OD650 of the cell culture in Luria-Bertani medium in the
presence or absence of test compound) of each compound were determined
for E. coli Mc4100. Cells were grown in maltose-glycerol
minimal medium overnight at 37°C, diluted in fresh medium to an
OD550 of 0.1, and then grown at 30°C to mid-log phase.
The cell cultures were grown in the absence of or in the presence of
0.25 times the MIC of the compound of interest for 15 and 30 min and
labeled for 10 s with 60 µCi of [35S]methionine
(1,175 Ci/mmol; NEN, Boston, Mass.) (31). A methionine chase
was initiated by addition of an equal volume of unlabeled 1%
methionine, and samples were taken at 0.25, 0.5, 1, 2, and 5 min.
Samples were added to 1/10 volume of 100% trichloroacetic acid (TCA)
(wt/vol), precipitated by microcentrifugation, washed in acetone, and
solubilized in 1.0% SDS-1 mM EDTA-10 mM Tris, pH 7.5. Samples were
boiled, vortexed vigorously, and frozen at
70°C. Thawed samples
were then microcentrifuged at 16,000 × g for 5 min, and the
supernatants were transferred to a new tube. Twenty microliters of
extract was added to 650 µl of 2.0% Triton X-100-0.1 mM EDTA-50 mM
Tris (pH 8.0)-0.15 M NaCl. One microliter of anti-MBP antibody (New
England Biolabs, Beverly, Mass.) was added and samples were rocked
overnight at 4°C. Samples were mixed with 50 µl of Igsorb (The
Enzyme Center, Malden, Mass.), washed, resuspended in 2× sample
loading buffer, and electrophoresed in an SDS-11% polyacrylamide gel
(16). The gel was stained with Coomassie blue, soaked in
1.0% glycerol, dried, and exposed to X-Omat film (Eastman Kodak
Company, Rochester, N.Y.) for 3 to 8 days. The following compounds were
used at the indicated concentrations cerulenin, 2.5 µg/ml;
chloramphenicol, 0.25 µg/ml; polymyxin B, 2.5 µg/ml; compound 3, 16 µg/ml; compound 5, 8 µg/ml; and compound 6, 16 µg/ml. These
concentrations were estimated from growth curves to be 0.25 to 0.5 times the MICs, respectively.
Incorporation of radiolabeled precursors. Macromolecular synthesis by E. coli imp was studied by measuring the incorporation of the appropriate radiolabeled precursors into TCA-precipitable material (40). An E. coli strain carrying an imp mutation was grown at 37°C to an OD600 (10-mm path length) of 0.2 in modified minimal medium. Aliquots of 100 µl were dispensed into microtiter wells containing the compounds of interest (see Table 2), and the plates were incubated for 10 min at 37°C with vigorous agitation. Cells were pulse labeled for 5 min by adding the following radiolabeled precursors at the indicated final concentrations: [3H]thymidine, 2.5 µCi/ml (90 Ci/mM; Amersham Corporation, Arlington Heights, Ill.) with 0.06 µg of unlabeled thymidine/ml; [3H]uridine, 2.5 µCi (49 Ci/mM; Amersham Corporation) with 0.2 µg of unlabeled uridine/ml; or 3H-labeled amino acids, 6.67 µCi/ml (mixture of leucine, lysine, phenylalanine, proline, and tyrosine with specific activities of 135, 83, 123, 103, and 118 Ci/mmol, respectively; Amersham Corporation). One hundred microliters of chilled TCA (10%) supplemented with 0.5 mg of unlabeled precursors per ml was added to each well, and the plate was immediately refrigerated for 1 h. The precipitate was collected on a glass fiber filter (filtermat B; model no. 1205-404; Wallac) using a Skatron Micro-96 cell harvester (model 1118) programmed for a 3-s prewetting with chilled distilled water, followed by a 12-s wash with 5% chilled TCA and a 5-s drying cycle. To assess the effects of the test compounds on cellular uptake of radiolabeled precursors, the addition of TCA to the microtiter plate was eliminated, and the contents of each well were harvested onto a glass fiber filter by the harvester programmed for a 3-s prewetting, a 12-s wash with chilled normal saline (0.9% NaCl in deionized water), and a 5-s drying cycle. Filter mats were dried for 7 min at high power in a microwave oven (700 W; Quasar), solid scintillant (MeltilexB; Pharmacia model no. 1205-402) was applied, and the isotope that was retained on the filter was quantitated in an LKB Betaplate scintillation counter (Wallac model no. 1205). The levels of incorporation of [3H]thymidine, [3H]uridine, and 3H-labeled amino acids were expressed as the percent of that of the untreated control.
Effect on intracellular K of E. coli imp. To assess potential membrane disruption by the test compounds, the affects on the intracellular potassium in E. coli imp was studied in a saline buffer (10 mM HEPES [pH 7.0], 150 mM NaCl, and 0.1 mM KCl [pH 7.0]) (1). A log-phase culture was washed twice with saline buffer, and the pellet was resuspended in the same buffer to an OD600 (path length of 10 mm) of 2.00. One milliliter of the bacterial suspension was treated with test compound at various concentrations for 1 h, and cells were pelleted by centrifugation (at 10,000 × g for 2 min). The resulting supernatant was diluted 1:10 in high-performance liquid chromatography-grade water and analyzed for potassium ions by atomic absorption spectrophotometry (Instrumentation Laboratories model 551 spectrophotometer). For the determination of the total potassium level, 1 ml of the culture was hydrolyzed in 2 M sulfuric acid with heat (100°C, for 1 h), chilled for 1 h, and centrifuged (at 10,000 × g for 2 min). The supernatant was then diluted 1:10 and analyzed for potassium content.
Lysis of human RBCs. One milliliter of freshly pooled human blood was centrifuged (at 10,000 × g for 2 min), and the pellet was washed four times with normal saline by repeated resuspension and centrifugation. The final pellet was resuspended in 1 ml of RBC buffer (10 mM sodium phosphate [pH 7.4], 150 mM NaCl, 1 mM MgCl2) (1). Twenty-five microliters of the RBC suspension was added to the microcentrifuge tube containing 1 ml of drug solution (final concentration ranging from 1 to 128 µg/ml) prepared in duplicate in RBC buffer. After 2 h of treatment, the content of the tube was centrifuged (at 10,000 × g for 2 min) and the OD540 (10-mm pathlength) of the supernatant was measured. To acheive 100% lysis, 25 µl of RBC suspension was added to 1 ml of water.
| |
RESULTS |
|---|
|
|
|---|
Design of a SecA-
-galactosidase fusion reporter system and
assay protocol.
E. coli strain MM171-2 carries a
secA-lacZ fusion at the normal chromosomal secA
locus and can be used to detect autoregulation of SecA translation
(25, 31). The strain also carries
PR9, which provides
wild-type SecA function. When secretion is disrupted, an increase in
-galactosidase activity due to induction of SecA expression can be
measured using ONPG as a substrate (21). This system was
developed into a high-throughput assay in which compounds and natural
product extracts could be screened for protein secretion inhibitory
activity (see Materials and Methods).
-galactosidase expression three- to fivefold over background levels.
Compounds which gave a fold induction value of 1.4-fold or greater
(i.e., a ratio of expression in the presence of inhibitor/expression in
the absence of inhibitor) were considered potential secretion inhibitors. This value was chosen as a cut-off based on the observed sensitivity and reproducibility of the assay.
Inhibitory activity was confirmed by a dose response assay, and
subsequent secondary analysis was carried out as described below.
Compounds of interest were identified based on induced expression of
the secA-lacZ reporter to a level of 1.4-fold over
background. Of the two natural product extracts which caused induction,
one contained a previously identified compound, pyrroindomycin
(compound 7 [Fig. 3]) which was
previously shown to have significant antimicrobial activity in vitro
but to lose activity in the presence of serum (39).
|
128 µg/ml, and these compounds
underwent secondary analyses to study their mechanism of action. Six
diverse representative structures are shown in Fig. 3. A structural
motif common to structures 1, 3, and 5 is the presence of imino
moieties. The presence of lipophilic characteristics appear to be a
common structural feature of the entire set. It should be noted that
sulochrin bears a gross structural similarity to compounds 2, 3, and 4 in that they all contain geminal diphenyl groups.
|
ELISA and Western analysis demonstrated inhibition of secretion by
selected compounds.
Because inhibitors of secretion should
decrease the amount of extracellular protein released into the medium
in vitro, ELISA and Western analyses were used to quantitate the amount
of TSST-1 secreted by strain MN8 in the presence or absence of the
compounds of interest. TSST-1 contains a signal sequence, and
presumably is secreted via the Sec-dependant pathway (3). To
analyze the effect of the potential synthetic secretion inhibitors on
TSST-1 secretion, MN8 was grown in the presence of inhibitory
concentrations of the compounds for 6 h. Cell extracts and media
were examined by Western analysis or by ELISA immunoprecipitation using
an antibody to TSST-1 to identify effects on production or localization
of the protein. The effects of the compounds can be divided into two
categories: those which show a clear inhibition of secretion of TSST-1
and those for which this assay does not give definitive results. For
the latter compounds an affect on a metabolic step before secretion,
for example, translation, cannot be ruled out. Examples of each
category are shown in Fig. 4.
|
Pulse-chase labeling and immunoprecipitation of MBP in E. coli Mc4100 in the presence of potential secretion
inhibitors.
In order to further elucidate the mechanism of action
of the putative secretion inhibitors, an examination of the expression and localization of the secreted protein MBP in E. coli was
performed. Cells were labeled at 0.25 to 0.5 times the MIC for test
compounds, and MBP was detected by immunoprecipitation. Several
antimicrobial agents with known mechanisms of action were used as
reference compounds. Cerulenin, which inhibits secretion in E. coli as a result of a deleterious effect on fatty acid synthesis
(19), causes a decreased expression of MBP at 15 min (Fig.
5A). After 30 min, the level of mature
MBP was significantly less than in the absence of drug. There was
little if any accumulation of precursor protein, as is often detected
in secretion mutants (see discussion). Chloramphenicol, an inhibitor of
prokaryotic protein synthesis (17, 28), also caused an
inhibition of MBP expression (Fig. 5B). There seemed not to be a
specific accumulation of precursor protein but rather an overall
decrease in MBP levels by 15 min of exposure. Because secretion occurs
at the membrane and membrane-damaging agents could potentially give
false-positive results in this secretion inhibitor assay, polymyxin B,
which causes bacterial membrane damage (5), was also tested
(Fig. 5C). This compound caused a quick and significant decrease in the
level of mature MBP detected in the cell.
|
Membrane activity and eukaryotic toxicity of selected putative
secretion inhibitors.
Many of the compounds identified in the
high-throughput screen for secretion inhibitors were found to cause
toxicity in tissue culture: >75% inhibition of growth at 10 µg/ml
in more than one cell type, e.g., Vero and human foreskin fibroblast
cell lines (data not shown). Therefore, as shown in Table
2, the four compounds believed to inhibit
secretion by the previous analyses were assessed for their affect on
metabolic precursor uptake and incorporation. Each was found to cause
nonspecific decreases in the in vivo labeling of DNA, RNA, and protein.
This pattern of inhibition suggests general membrane damage. Moreover,
a semisynthetic diacetyl derivative of pyrroindomycin (39),
which was positive in the secretion inhibition screen (data not shown),
has previously been shown to cause membrane damage.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
In an era when increased bacterial resistance to existing
antibiotics threatens to impede successful chemotherapy, identification of inhibitors of novel antibacterial targets is critical. Such targets
should be highly conserved among prokaryotes, not conserved among
eukaryotes, essential, and well defined. The secretion pathway meets
all of these criteria (22, 41). The method described here
takes advantage of a whole-cell system in which several targets of a
multicomponent system can be attacked at once. Induced expression of
SecA has been documented under both genetic and chemically induced
conditions which cause secretion inhibition (9, 24, 25, 35).
Therefore, chemical inhibition of any of the Sec proteins besides SecB
should give a positive signal using the SecA-
-galactosidase fusion protein.
Western blot and ELISA analyses of TSST-1 secretion in S. aureus were used as the initial secondary assays to identify bona fide secretion inhibitors in this screen. Both of these assays utilize immunological detection of TSST-1. While the ELISA enables quick high-throughput screening, the Western blot technique offers a visual analysis of secreted or retained TSST-1. In both cases, monitoring the growth rate of the cells often allows dissection of the narrow window between inhibition of an essential process, i.e., secretion, and growth inhibition. Interestingly, in at least the case of inhibition by cerulenin, the Western blot suggests a specific feedback inhibition to translation of secreted proteins, as demonstrated by the level of TSST-1 in the cellular compartment. A connection between inhibition of translation and secretion has been documented before in a secA(Am) mutant (24). One shortcoming to these assay techniques is the need for a control for general translation inhibition. In some cases, recognition of a protein other than TSST-1 in the cellular extract by the primary antibody was assumed to be a valid control for protein translation.
A further and more laborious analysis of compounds identified in this screen was pulse-chase labeling and immunoprecipitation. Many examples exist in the literature in which this technique was used to analyze the effects of secretion mutants on the expression and localization of various secreted proteins (7, 24, 25, 29, 32, 37, 44). In particular, accumulation of precursor to the MBP has been demonstrated in mutants of secA, secY, secD, and secF (7, 24, 25, 29, 32, 37, 44). Additionally, sodium azide was previously shown to cause precursor accumulation in E. coli (25). The fact that only a subset of the compounds identified here cause precursor accumulation begs the question as to how their effect differs from those that do not, including cerulenin, which affects secretion as a by-product of its effect on lipid biosynthesis. Previous reports described some mutations in secA and secY that likewise did not cause accumulation (32). It was hypothesized that those mutations might affect the overexpression of SecA without affecting secretory function or, alternatively, that the debilitating effects of the mutations might be overcome by SecA overexpression. Similarly, the compounds described here might act by one of these mechanisms. The possibility exists, however, that the effect on SecA expression caused by these compounds is pleiotropic and that their site of action is unrelated to secretion. It would be interesting to determine if mutants that are resistant to these specific inhibitors can be isolated. If alterations are found in the secretory machinery, it could provide more detailed information regarding the mode of action of these compounds.
All of the compounds presented as secretion inhibitors in this study appear to have nonspecific effects on the integrity of both prokaryotic and eukaryotic membranes. This observation raises some concerns about the utility of targeting membrane-bound proteins without considering effects on membrane integrity. All of the proteins targeted in this assay are at least peripherally membrane associated. It is possible, if not likely, that membrane-damaging agents will negatively affect membrane-associated proteins and be noted as positive in screens for inhibitors of these targets. It is of interest that several of the compounds presented here bear striking structural similarity to some of the hydrophobic tyramine derivatives identified by Barrett et al. as inhibitors of a sensor kinase (2). Although those compounds were identified in vitro, they are also targeted against a membrane protein. There is evidence to suggest that they too have multiple deleterious effects on cellular integrity (12).
The data presented here demonstrate the power of whole-cell screens utilizing reporter fusion proteins to identify inhibitors of different members of a complex pathway. Use of an induced enzyme as a positive signal enables in many cases the dissection of the tight linkage between an inhibitory process and death. While the compounds identified in this screen had pleotropic effects on cell viability, evidence presented here suggests that they are bona fide secretion inhibitors, and thus the secretion pathway is indeed a valid target for antibacterial chemotherapy.
| |
ACKNOWLEDGMENTS |
|---|
The participation of Amy Ashline, James LaRocque, John Morin, and Pedro Sobers in this study is gratefully acknowledged. We thank Beth Rasmussen, Elizabeth Glasfeld, and Chris Murphy for critical reading of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Wyeth-Ayerst Research, 401 Middletown Rd., Pearl River, NY 10965. Phone: (914) 732-5601. Fax: (914) 732-2480. E-mail: alksnel{at}war.wyeth.com.
Present address: Regeneron Pharmaceuticals, Tarrytown, N.Y.
Present address: Periodontix, Watertown, Mass.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Abbanat, D. A., M. P. Singh, and M. Greenstein. 1998. Hongoquercins, new antibacterial agents from the fungus LL-23G227: fermentation and biological activity. J. Antibiot. 51:708-714[Medline]. |
| 2. |
Barrett, J. F.,
R. M. Goldschmidt,
L. E. Lawrence,
B. Foleno,
R. Chen,
J. P. Demers,
S. Johnson,
R. Kanojia,
J. Fernandez,
J. Bernstein,
L. Licata,
A. Donetz,
S. Huang,
D. J. Hlasta,
M. J. Macielag,
K. Ohemeng,
R. Frechette,
M. B. Frosco,
D. H. Klaubert,
J. M. Whiteley,
L. Wang, and J. A. Hoch.
1998.
Antibacterial agents that inhibit two-component signal transduction systems.
Proc. Natl. Acad. Sci. USA
95:5317-5322 |
| 3. |
Blomster-Hautamaa, D. A.,
B. N. Kreiswirth,
J. S. Kornblum,
R. P. Novick, and P. M. Schlievert.
1986.
The nucleotide and partial amino acid sequence of toxic shock syndrome toxin-1.
J. Biol. Chem.
261:15783-15786 |
| 4. | Casadaban, M. J., and S. N. Cohen. 1980. Analysis of gene control signals by DNA fusion and cloning in Escherichia coli. J. Mol. Biol. 138:179-207[CrossRef][Medline]. |
| 5. |
Chopra, I., and K. Hacker.
1992.
Uptake of minocycline by Escherichia coli.
J. Antimicrob. Chemother.
29:19-25 |
| 6. | Curtis, R. F., P. C. Harries, C. H. Hassall, and J. D. Levi. 1964. The biosynthesis of phenols. 5. The relationships of some phenolic metabolites of mutants of Aspergillus terreus Thom, I.M.I. 16043. Biochem. J. 90:43-51[Medline]. |
| 7. |
Danese, P. N.,
C. K. Murphy, and T. J. Silhavy.
1995.
Multicopy suppression of cold-sensitive sec mutations in Escherichia coli.
J. Bacteriol.
177:4969-4973 |
| 8. | Den Blaauwen, T., and A. J. M. Driessen. 1996. Sec-dependent preprotein translocation in bacteria. Arch. Microbiol. 165:1-8[CrossRef][Medline]. |
| 9. |
Gardel, C.,
S. Benson,
J. Hunt,
S. Michaelis, and J. Beckwith.
1987.
SecD, a new gene involved in protein export in Escherichia coli.
J. Bacteriol.
169:1286-1290 |
| 10. | Gorlich, D., and T. A. Rapoport. 1993. Protein translocation into proteoliposomes reconstituted from purified components of the endoplasmic reticulum membrane. Cell 75:615-630[CrossRef][Medline]. |
| 11. | Hartmann, E., T. Sommer, S. Prehn, D. Gorlich, S. Jentsch, and T. A. Rapoport. 1994. Evolutionary conservation of components of the protein translocation complex. Nature (London) 367:654-657[CrossRef][Medline]. |
| 12. |
Hilliard, J. J.,
R. Goldschmidt,
L. Licata,
E. Z. Baum, and K. Bush.
1999.
Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems.
Antimicrob. Agents Chemother.
43:1693-1699 |
| 13. | Inamori, Y., Y. Kato, M. Kubo, T. Kamiki, T. Takemato, and K. Namoto. 1983. Studies on metabolites produced by Aspergillus terreus var. aureus. I. Chemical structures and antimicrobial activities of metabolites isolated from culture broth. Chem. Pharm. Bull. 31:4543-4548. |
| 14. | Klein, M., J. Meens, and R. Freudl. 1995. Functional characterization of the Staphylococcus carnosus SecA protein in Escherichia coli and Bacillus subtilis secA mutant strains. FEMS Microbiol. Lett. 131:271-277[CrossRef][Medline]. |
| 15. | Koivula, T., I. Palva, and H. Hemila. 1991. Nucleotide sequence of the secY gene from Lactococcus lactis and identification of conserved regions by comparison of four SecY proteins. FEBS Lett. 288:114-118[CrossRef][Medline]. |
| 16. | Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature (London) 277:680-685. |
| 17. |
Lessard, J. L., and S. Pestka.
1972.
Studies on the formation of transfer ribonucleic acid-ribosome complexes. XXIII. Chloramphenicol, aminoacyl-oligonucleotides, and Escherichia coli ribosomes.
J. Biol. Chem.
247:6909-6912 |
| 18. | Mantsala, P. 1982. Inhibition of protein secretion by cerulenin in Bacillus subtilis. J. Gen. Microbiol. 128:2967-2972[Medline]. |
| 19. |
Mantsala, P., and J. Lehtinen.
1982.
Secretion of -lactamase by Escherichia coli in vivo and in vitro: effect of cerulenin.
Antonie Leeuwenhoek
48:353-364.
|
| 20. | McNicholas, P., R. Salavati, and D. Oliver. 1997. Dual regulation of Escherichia coli secA translation by distinct upstream elements. J. Mol. Biol. 265:128-141[CrossRef][Medline]. |
| 21. | Miller, J. H. 1992. A short course in bacterial genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 22. | Misra, R., and T. Silhavy. 1992. Protein secretion in bacteria: a chemotherapeutic target?, p. 163-175. In J. Sutcliffe, and N. Georgopapadakou (ed.), Emerging targets in antibacterial and antifungal therapy. Chapman and Hall, New York, N.Y. |
| 23. | National Committee for Clinical Laboratory Standards. 1977. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2. National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 24. | Oliver, D. B., and J. Beckwith. 1981. E. coli mutant pleiotropically defective in the export of secreted proteins. Cell 25:765-772[CrossRef][Medline]. |
| 25. | Oliver, D. B., and J. Beckwith. 1982. Regulation of a membrane component required for protein secretion in Escherichia coli. Cell 30:311-319[CrossRef][Medline]. |
| 26. |
Oliver, D. B.,
R. J. Cabelli,
K. M. Dolan, and G. P. Jarosik.
1990.
Azide-resistant mutants of Escherichia coli alter the SecA protein, an azide-sensitive component of the protein export machinery.
Proc. Natl. Acad. Sci. USA
87:8227-8231 |
| 27. | Overhoff, B., M. Klein, M. Spies, and R. Freudl. 1991. Identification of a gene fragment which codes for the 364 amino-terminal amino acid residues of a SecA homologue from Bacillus subtilis: further evidence for the conservation of the protein export apparatus in gram-positive and gram-negative bacteria. Mol. Gen. Genet. 228:417-423[CrossRef][Medline]. |
| 28. | Pestka, S. 1975. Chloramphenicol, p. 396. In J. W. Corcoran, and F. E. Hahn (ed.), Antibiotics, vol. 3. Springer-Verlag, New York, N.Y. |
| 29. | Pogliano, K. J., and J. Beckwith. 1993. The Cs sec mutants of Escherichia coli reflect the cold sensitivity of protein export itself. Genetics 133:763-773[Abstract]. |
| 30. |
Pugsley, A. P.
1993.
The complete general secretory pathway in gram-negative bacteria.
Microbiol. Rev.
57:50-108 |
| 31. |
Rasmussen, B. A.,
C. H. MacGregor,
P. H. Ray, and P. J. Bassford, Jr.
1985.
In vivo and in vitro synthesis of Escherichia coli maltose-binding protein under regulatory control of the lacUV5 promoter-operator.
J. Bacteriol.
164:665-673 |
| 32. |
Riggs, P. D.,
A. I. Derman, and J. Beckwith.
1988.
A mutation affecting the regulation of a secA-lacZ fusion defines a new sec gene.
Genetics
118:571-579 |
| 33. | Salavati, R., and D. Oliver. 1997. Identification of elements on GeneX-secA RNA of Escherichia coli required for SecA binding and secA auto-regulation. J. Mol. Biol. 265:142-152[CrossRef][Medline]. |
| 34. | Saleh, F. A. K., and J. H. Freer. 1984. Inhibition of secretion of staphylococcal alpha toxin by cerulenin. J. Med. Microbiol. 18:205-216[Abstract]. |
| 35. |
Schatz, P. J.,
P. D. Riggs,
A. Jacq,
M. J. Fath, and J. Beckwith.
1989.
The secE gene encodes an integral membrane protein required for protein export in Escherichia coli.
Genes Dev.
3:1035-1044 |
| 36. | Schlievert, P. M., and D. A. Blomster. 1983. Production of staphylococcal pyrogenic exotoxin type C: influence of physical and chemical factors. J. Infect. Dis. 147:236-242[Medline]. |
| 37. | Shimoike, T., Y. Akiyama, T. Baba, T. Taura, and K. Ito. 1992. SecY variants that interfere with Escherichia coli protein export in the presence of normal secY. Mol. Microbiol. 6:1205-1210[Medline]. |
| 38. | Silhavy, T. J., M. L. Berman, and L. W. Enquist. 1984. Experiments with gene fusions. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 39. | Singh, M. P., P. J. Petersen, N. V. Jacobus, M. J. Mroczenski-Wildey, W. M. Maiese, M. Greenstein, and D. A. Steinberg. 1994. Pyrroindomycins, novel antibiotics produced by Streptomyces rugosporus LL-42D005. J. Antibiot. 47:1258-1265[Medline]. |
| 40. |
Singh, M. P.,
P. J. Petersen,
N. V. Jacobus,
W. M. Maiese,
M. Greenstein, and D. A. Steinberg.
1994.
Mechanistic studies and biological activity of bioxalomycin alpha 2, a novel antibiotic produced by Streptomyces viridodiastaticus subsp. "litoralis" LL-31F508.
Antimicrob. Agents Chemother.
38:1808-1812 |
| 41. |
Stephens, C., and L. Shapiro.
1997.
Bacterial protein secretion a target for new antibiotics?
Chem. Biol.
4:637-641[CrossRef][Medline].
|
| 42. | Suh, J. W., S. A. Boylan, S. M. Thomas, K. M. Dolan, D. B. Oliver, and C. W. Price. 1990. Isolation of a secY homologue from Bacillus subtilis: evidence for a common protein export pathway in eubacteria. Mol. Microbiol. 4:305-314[CrossRef][Medline]. |
| 43. |
Takamatsu, H.,
S. Fuma,
K. Nakamura,
Y. Sadaie,
A. Shinkai,
S. Matsuyama,
S. Mizyshima, and K. Yamane.
1992.
In vivo and in vitro characterization of the secA gene product of Bacillus subtilis.
J. Bacteriol.
174:4308-4316 |
| 44. | Traxler, B., and C. Murphy. 1996. Insertion of the polytopic membrane protein MalF is dependent on the bacterial secretion machinery. J. Biol. Chem. 27:12394-12400. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |